Critical Contrast: argenx (NASDAQ:ARGX) & Tcr2 Therapeutics (NASDAQ:TCRR)

argenx (NASDAQ:ARGX) and Tcr2 Therapeutics (NASDAQ:TCRR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

argenx has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Tcr2 Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for argenx and Tcr2 Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenx 0 2 14 0 2.88
Tcr2 Therapeutics 0 0 3 0 3.00

argenx presently has a consensus price target of $220.40, indicating a potential downside of 2.14%. Tcr2 Therapeutics has a consensus price target of $19.00, indicating a potential upside of 21.87%. Given Tcr2 Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tcr2 Therapeutics is more favorable than argenx.

Earnings & Valuation

This table compares argenx and Tcr2 Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
argenx $78.17 million 135.44 -$182.52 million ($4.73) -47.62
Tcr2 Therapeutics N/A N/A -$47.60 million ($4.62) -3.37

Tcr2 Therapeutics has lower revenue, but higher earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Tcr2 Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares argenx and Tcr2 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
argenx N/A N/A N/A
Tcr2 Therapeutics N/A -32.20% -30.77%

Institutional & Insider Ownership

54.5% of argenx shares are owned by institutional investors. Comparatively, 59.2% of Tcr2 Therapeutics shares are owned by institutional investors. 39.1% of Tcr2 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Tcr2 Therapeutics beats argenx on 8 of the 12 factors compared between the two stocks.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

About Tcr2 Therapeutics

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with's FREE daily email newsletter.